Overview
- Topline results from ACHIEVE-2 and ACHIEVE-5 showed significant A1C reductions and weight loss in adults with type 2 diabetes, meeting all primary and key secondary endpoints at 40 weeks.
- In ACHIEVE-2, orforglipron reduced A1C by up to about 1.7 percentage points versus roughly 0.8 points with dapagliflozin (Farxiga) in patients inadequately controlled on metformin.
- In ACHIEVE-5, orforglipron lowered A1C by up to about 2.1 percentage points versus roughly 0.8 points with placebo in patients on titrated insulin glargine, with or without metformin and/or an SGLT2 inhibitor.
- Lilly reported improvements in cardiovascular risk factors and a safety profile consistent with prior studies, with mostly mild-to-moderate gastrointestinal events, discontinuation rates in line with earlier data, and no hepatic safety signal observed.
- Detailed data will be presented at a future medical meeting, and the final registration study, ACHIEVE-4, is expected to read out in the first quarter of 2026.